Search clinical trials for: Metastatic TNBC

Total 14583 results

Biotheus Inc.

Not yet recruiting

PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic Triple-negative Breast Cancer

Triple Negative Breast Cancer(TNBC)

China
Assistance Publique - Hôpitaux de Paris

Not yet recruiting

Association of Pembrolizumab Infusion Time and Efficacy in Patients With Non-metastatic Triple-negative Breast Cancer (TNBC) Treated With Neoadjuvant Chemotherapy and Immunotherapy (PEMCLOCK)

Non-Metastatic Breast Carcinoma
Fudan University

Recruiting

LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer

TNBC - Triple-Negative Breast Cancer

China
The Netherlands Cancer Institute
Hoffmann-La Roche

Not yet recruiting

NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial (TONIC-3)

Metastatic Breast Cancer
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of Pembrolizumab and Cryoablation in People With Breast Cancer

Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | Breast Cancer Stage IV | Locally Advanced Breast Cancer | Metastatic Triple-Negative Breast Carcinoma | Locally Advanced Triple-Negative Breast Carcinoma

United States
Rhizen Pharmaceuticals SA
Incozen Therapeutics Pvt Ltd

Recruiting

Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC)

Triple Negative Breast Cancer (TNBC)

India
Huihua Xiong

Recruiting

The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ：Single-arm, Prospective, Open Clinical Study (UTILIZABLE)

TNBC - Triple-Negative Breast Cancer

China
OncoNano Medicine, Inc.

Recruiting

A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. (ON-5001)

Lymphoma, Non-Hodgkin | Follicular Lymphoma | Carcinoma in Situ | Mantle Cell Lymphoma | Metastatic Cancer | Bladder Cancer | Skin Cancer | Triple Negative Breast Cancer | Cervix Cancer | Diffuse Large B Cell Lymphoma | Head and Neck Squamous Cell Carcinoma | Tumor, Solid | Tumor Recurrence | Uveal Melanoma, Recurrent

United States
Ministry of Health, Saudi Arabia
Maher M.akl

Not yet recruiting

Targeting Metastatic Breast Cancers by Alkaline Glucosodiene Molecules Via a Metabolic Pathway Phase I Clinical Trial

TNBC - Triple-Negative Breast Cancer
Fudan University

Recruiting

Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) Subtype (BCTOP-T-M03)

Metastatic Breast Cancer | Triple Negative Breast Cancer | Mutation

China
Fudan University

Not yet recruiting

T-DXd in the First-Line Treatment of Locally Advanced or Metastatic TNBC-LAR HER2-low Patients

Triple-Negative Breast Cancer

China
Fudan University

Not yet recruiting

An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC in First-line Treatment (FUTURE-Trop2)

TNBC - Triple-Negative Breast Cancer
University Hospital Tuebingen
University Hospital Freiburg; University Hospital Ulm

Recruiting

Immunotherapy-related CRP Kinetics in Early and Metastatic Triple-negative Breast Cancer

TNBC - Triple-Negative Breast Cancer

Germany
Sapience Therapeutics

Recruiting

A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors

Hepatocellular Carcinoma | Pancreatic Cancer | Ovarian Cancer | Cholangiocarcinoma | Triple Negative Breast Cancer | Metastatic Melanoma | Colon Cancer | Synovial Sarcoma | Breast Cancer Metastatic | Metastatic Colon Cancer | Melanoma Stage IV | Melanoma Recurrent | TNBC - Triple-Negative Breast Cancer | NSCLC, Metastatic and other conditions

United States
Fondazione per la Medicina Personalizzata
University of Roma La Sapienza

Recruiting

TIP in Patients Affected by Metastatic TNBC (TIP)

Metastatic Triple-negative Breast Cancer

Italy
Fudan University

Recruiting

Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer (BCTOP-T-M01)

Triple-Negative Breast Cancer

China
Fudan University

Recruiting

Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.

Triple-Negative Breast Cancer

China
Huihua Xiong

Not yet recruiting

Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast Cancer

Metastatic Triple-negative Breast Cancer

China
Mabpro, a.s.

Not yet recruiting

Clinical Study to Evaluate Safety and Dosing of CA9hu-1 in Patients With Advanced Solid Tumours (CAMP1)

Head and Neck Cancer | Mesothelioma, Malignant | TNBC - Triple-Negative Breast Cancer | Non-small-cell Lung Carcinoma | Clear Cell Renal Cell Carcinoma Metastatic
The Methodist Hospital Research Institute
Novartis Pharmaceuticals

Recruiting

Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)

Metastatic Breast Cancer | HER2-negative Breast Cancer | TNBC - Triple-Negative Breast Cancer | Metaplastic Breast Carcinoma

United States
Genentech, Inc.

Recruiting

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Melanoma | Cervical Cancer | HCC | Gastric Cancer | Esophageal Cancer | NSCLC | Urothelial Carcinoma | HNSCC | Locally Advanced or Metastatic Solid Tumors | TNBC | Clear Cell RCC

Korea, Republic of, Netherlands, Spain, United States, Australia, Canada, Belgium
Shanghai Jiaolian Drug Research and Development...
Shanghai Pharmaceuticals Holding Co., Ltd

Recruiting

Study of B013 and Nab-Paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer

Triple Negative Breast Cancer (TNBC)

China
University of Utah
United States Department of Defense

Recruiting

Functional Precision Oncology to Predict, Prevent, and Treat Early Metastatic Recurrence of TNBC (TOWARDS-II)

Breast Cancer Recurrent

United States
Zhejiang Cancer Hospital
Sun Yat-sen University; Fujian Cancer Hospital; Hunan Cancer Hospital; Zhejiang... and other collaborators

Not yet recruiting

Phase II Study of Niraparib in Metastatic TNBC Patients With Homologous Recombination Deficiency

Triple Negative Breast Cancer | Homologous Recombination Deficiency
Fundacio Clinic Barcelona
SOLTI Breast Cancer Research Group

Not yet recruiting

Treatment of Advanced or Metastatic Triple-negative Breast Cancer With Adoptive Therapy of PD1+ TILS (TILS001)

Metastatic Triple-Negative Breast Carcinoma

Spain
Beijing 302 Hospital

Recruiting

Study of Eribulin in Combination With Anti-PD-1 Antibody in Patients With Metastatic Triple-Negative Breast Cancer

TNBC - Triple-Negative Breast Cancer

China
Antonio Giordano, MD
Cardiff Oncology

Recruiting

Onvansertib + Paclitaxel In TNBC

Breast Cancer | Metastatic Breast Cancer | Inflammatory Breast Cancer | Invasive Breast Cancer | Locally Advanced Breast Cancer | Unresectable Breast Carcinoma | HER2-negative Breast Cancer | Triple Negative Breast Cancer (TNBC) | Hormone Receptor Negative Breast Carcinoma | Hormone Receptor/Growth Factor...

United States
Yuan Yuan
Gateway for Cancer Research; Agenus Inc.

Recruiting

Ivermectin and Balstilimab for the Treatment of Metastatic Triple Negative Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic Triple-Negative Breast Carcinoma

United States
Fudan University

Recruiting

Cryoablation Combined With Tirelizumab and Bevacizumab in Liver Metastatic TNBC Patients Failed by Multiline Therapy (Castle06(BC))

Metastatic Breast Cancer in the Liver

China
Lyell Immunopharma, Inc.

Recruiting

A Study to Investigate LYL797 in Adults With Solid Tumors

Advanced Breast Cancer | NSCLC | Non Small Cell Lung Cancer | Triple Negative Breast Cancer | Non-small Cell Lung Cancer | Advanced Lung Carcinoma | Non Small Cell Lung Cancer Metastatic | NSCLC Stage IV | Recurrent Breast Cancer | TNBC - Triple-Negative Breast Cancer | Relapsed Cancer | NSCLC, Recurrent | Recurrent... and other conditions

United States
First Affiliated Hospital Bengbu Medical College

Recruiting

Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC

Triple-negative Breast Cancer

China
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co...

Recruiting

A Study of FDA018-ADC in Patients With Advanced Solid Tumors

Advanced/ Metastatic Solid Tumors

China
Nurix Therapeutics, Inc.

Recruiting

A Study of NX-1607 in Adults With Advanced Malignancies

Cervical Cancer | Gastric Cancer | Head and Neck Squamous Cell Carcinoma | Non-small Cell Lung Cancer (NSCLC) | Metastatic Urothelial Carcinoma | Ovarian Cancer, Epithelial | Metastatic Castration-resistant Prostate Cancer (mCRPC) | Triple Negative Breast Cancer (TNBC) | Malignant Pleural Mesothelioma... and other conditions

United States, United Kingdom
Medicenna Therapeutics, Inc.
Merck Sharp & Dohme LLC

Recruiting

A Beta-only IL-2 ImmunoTherapY Study (ABILITY-1)

Clear Cell Renal Cell Carcinoma | Cervical Cancer | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | Fallopian Tube Cancer | Solid Tumor | Squamous Cell Carcinoma of Head and Neck | Bladder Cancer | Skin Cancer | Triple Negative Breast Cancer | Advanced Solid Tumor | Primary Peritoneal Cancer | Endometrial Carcinoma and other conditions

United States, Australia, Korea, Republic of, Canada
Institut Cancerologie de l'Ouest
Telix Pharmaceutical; SIRIC ILIAD

Recruiting

Imaging Performance Assessment of 89Zirconium-labelled Girentuximab (89Zr-TLX250) PET-CT in Metastatic Triple Negative Breast Cancer Patients (OPALESCENCE)

Triple Negative Breast Cancer

France
Peter MacCallum Cancer Centre, Australia

Recruiting

Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast Cancer (BELLA)

Metastatic Triple Negative Breast Cancer

Australia
Transgene
Merck Sharp & Dohme LLC; BioInvent International AB

Recruiting

A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors

Melanoma | Soft Tissue Sarcoma | Non Small Cell Lung Cancer | Metastatic Cancer | Triple Negative Breast Cancer | Merkel Cell Carcinoma

France, Belgium
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer

Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | TNBC - Triple-Negative Breast Cancer

United States
National Cancer Centre, Singapore
National Medical Research Council (NMRC), Singapore

Recruiting

The Role of Bexarotene in Inducing Susceptibility to Chemotherapy in Metastatic TNBC

Metastatic Triple-Negative Breast Carcinoma

Singapore
Sichuan Baili Pharmaceutical Co., Ltd.
SystImmune Inc.

Recruiting

A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors

Solid Tumor

China
Dana-Farber Cancer Institute
Merck Sharp & Dohme LLC; Gilead Sciences

Recruiting

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

Breast Cancer | Triple Negative Breast Cancer | PD-L1 Negative

United States
Astellas Pharma Global Development, Inc.
Merck Sharp & Dohme LLC; Seagen Inc.

Recruiting

A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

Locally Advanced or Metastatic Malignant Solid Tumors

United States, Japan, Canada
The Netherlands Cancer Institute
Bristol-Myers Squibb

Recruiting

Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) Patients (TONIC-2)

Metastatic Breast Cancer

Netherlands
AbbVie

Recruiting

Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors

Advanced Solid Tumors Cancer

United States, Australia, Israel, Japan, Korea, Republic of, Puerto Rico, Spain, Taiwan, Canada, France, Belgium
AstraZeneca

Recruiting

A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer (BEGONIA)

Triple Negative Breast Neoplasms

United States, Korea, Republic of, Canada, Taiwan, United Kingdom, Poland
BioLite, Inc.

Not yet recruiting

Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer.

Triple Negative Breast Cancer
AbbVie

Active, not recruiting

A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

Cancer | Advanced Solid Tumors | Metastatic Solid Tumors | Triple-Negative Breast Cancer (TNBC) | Non-small-cell-lung-cancer (NSCLC)

United States, Australia, France, Israel, Spain, Taiwan
UNICANCER
National Cancer Institute, France

Active, not recruiting

Tracking Triple-negative Breast Cancer Evolution Through Therapy (TRACERX-TNBC)

Triple-Negative Breast Neoplasm

France
Regeneron Pharmaceuticals

Suspended

A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer

Non-Small Cell Lung Cancer | Triple Negative Breast Cancer | Merkel Cell Carcinoma | Basal Cell Carcinoma | Oropharynx Squamous Cell Carcinoma | Cutaneous Squamous Cell Carcinoma

United States, Australia
Celldex Therapeutics
Merck Sharp & Dohme LLC

Completed

A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies

Melanoma | Follicular Lymphoma | Renal Cell Carcinoma | Breast Cancer | Head and Neck Cancer | Gastric Cancer | Colorectal Cancer | Esophageal Cancer | Pancreatic Adenocarcinoma | Ovarian Cancer | Fallopian Tube Cancer | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Lymphoplasmacytic Lymphoma | Non-Hodgkin Lymphoma | ... and other conditions

United States

Search clinical trials for: Metastatic TNBC

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cambodia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations